324 related articles for article (PubMed ID: 18781120)
1. Laboratory evaluation of inflammatory bowel disease.
Wong A; Bass D
Curr Opin Pediatr; 2008 Oct; 20(5):566-70. PubMed ID: 18781120
[TBL] [Abstract][Full Text] [Related]
2. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
4. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
6. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.
Walker TR; Land ML; Kartashov A; Saslowsky TM; Lyerly DM; Boone JH; Rufo PA
J Pediatr Gastroenterol Nutr; 2007 Apr; 44(4):414-22. PubMed ID: 17414136
[TBL] [Abstract][Full Text] [Related]
7. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia.
Sabery N; Bass D
Pediatrics; 2007 Jan; 119(1):e193-9. PubMed ID: 17158948
[TBL] [Abstract][Full Text] [Related]
8. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
9. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
Kane SV; Sandborn WJ; Rufo PA; Zholudev A; Boone J; Lyerly D; Camilleri M; Hanauer SB
Am J Gastroenterol; 2003 Jun; 98(6):1309-14. PubMed ID: 12818275
[TBL] [Abstract][Full Text] [Related]
10. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
11. What is the role of serological markers in IBD? Pediatric and adult data.
Dubinsky M
Dig Dis; 2009; 27(3):259-68. PubMed ID: 19786750
[TBL] [Abstract][Full Text] [Related]
12. Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children.
Romano C; Famiani A; Gallizzi R; Comito D; Ferrau' V; Rossi P
Pediatrics; 2008 Dec; 122(6):e1278-81. PubMed ID: 19047226
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.
Long MD; Drossman DA
Am J Gastroenterol; 2010 Aug; 105(8):1796-8. PubMed ID: 20686466
[TBL] [Abstract][Full Text] [Related]
14. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Goldenberg BA; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
[TBL] [Abstract][Full Text] [Related]
15. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
Vucelic B
Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
[TBL] [Abstract][Full Text] [Related]
17. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines.
Waljee AK; Joyce JC; Wang S; Saxena A; Hart M; Zhu J; Higgins PD
Clin Gastroenterol Hepatol; 2010 Feb; 8(2):143-50. PubMed ID: 19835986
[TBL] [Abstract][Full Text] [Related]
18. Shortcomings of the inflammatory bowel disease Serology 7 panel.
Benor S; Russell GH; Silver M; Israel EJ; Yuan Q; Winter HS
Pediatrics; 2010 Jun; 125(6):1230-6. PubMed ID: 20439597
[TBL] [Abstract][Full Text] [Related]
19. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic.
Cabrera-Abreu JC; Davies P; Matek Z; Murphy MS
Arch Dis Child; 2004 Jan; 89(1):69-71. PubMed ID: 14709513
[TBL] [Abstract][Full Text] [Related]
20. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
Buckland MS; Mylonaki M; Rampton D; Longhurst HJ
Clin Diagn Lab Immunol; 2005 Nov; 12(11):1328-30. PubMed ID: 16275949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
